Liquidia Stock Surges 40% on $380.7M Litigation Settlement With UTHR

3-line summary

• Liquidia and United Therapeutics (UTHR) reached a global settlement resolving six pending lawsuits for a combined $380.7 million, with mutual releases and no admission of liability by either side, according to Investing.com. Liquidia's shares jumped about 40% in after-hours trading on the news.
• Liquidia's net payment is $175 million due within 30 business days, plus two $72.7 million installments due before January 31 and April 30, 2027; a separate $60.3 million covers Treprostinil Injection antitrust claimants this month. The settlement follows a September 30 Delaware federal court ruling that Liquidia infringed UTHR's patent on inhaled treprostinil for PH-ILD, which Liquidia will not appeal.
• Liquidia has filed a supplement to remove the PH-ILD indication from its YUTREPIA label. YUTREPIA will continue to be supplied to pulmonary arterial hypertension patients; preliminary unaudited Q3 2026 YUTREPIA net sales were $222.7 million, with $396.1 million in cash as of September 30.

This summary is our own processing of the source article; see the source link below for full context.